drugset / Trial / NCT00002388

A Study of 1592U89 in HIV-Infected Patients

NCT00002388

Phase 1 Completed 48 enrolled Glaxo Wellcome
Treatment

Summary

The purpose of this study is to see if it is safe to give 1592U89 to HIV-infected patients. This study also examines the effect 1592U89 has on plasma viral load (the level of HIV in the blood).

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Abacavir Other / unclassified